Skip to main content

Advertisement

SpringerLink
Log in

Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and “First Do No Harm” Part II

  • Prostate Cancer (S Prasad, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To discuss the overall and latest observations of the effect of diet, lifestyle, supplements, and some prescription heart healthy medications for prostate cancer prevention.

Recent Findings

The concept of maximizing heart health to prevent aggressive prostate cancer continues to be solidified with the addition of more prospective observational and randomized controlled trial data. Heart healthy is prostate healthy, and heart unhealthy is prostate unhealthy.

Summary

The primary goal of reducing the risk of all-cause and cardiovascular disease (CVD) morbidity and mortality also coincides with maximizing prostate cancer prevention. The obesity epidemic in children and adults along with recent diverse research has only strengthened the nexus between heart and prostate health. Greater dietary adherence toward a variety of healthy foods is associated with a graded improved probability of CVD and potentially aggressive cancer risk reduction. Preventing prostate cancer via dietary supplements should encourage a “first do no harm,” or less is more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer. Supplements to reduce side effects of some cancer treatments appear to have more encouraging data. A discussion of quality (QC) before utilizing any pill also requires attention. Medications or interventions that potentially improve heart health including statins, aspirin, and metformin (S.A.M.), specific beta-blocker medications, and even preventive vaccines are in general generic, low-cost, “natural,” and should continue to garner research interest. A watershed moment in medical education has arrived where the past perception of a diverse number of trees seemingly separated by vast distances, in reality, now appear to exist within the same forest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Flaxel CJ, Adelman RA, Bailey ST, Representative RS, Fawzi A, Representative MS, et al. Age-related macular degeneration preferred practice pattern. Ophthalmology. 2019. https://doi.org/10.1016/j.ophtha.2019.09.024.

  2. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373:1618–26.

    CAS  PubMed  Google Scholar 

  3. Matthews NM. Prohibited contaminants in dietary supplements. Sport Health. 2018;10:19–30.

    Google Scholar 

  4. Eurofins. https://www.eurofins.com Accessed 1 Nov 2019.

  5. Tested to Be Trusted. Accessed 1 Nov 2019. https://www.cvs.com/content/tested-trusted.

  6. Costa JG, Vidovic B, Saraiva N, do Ceu Costa M, Del Favero G, Marko D, et al. Contaminants: a dark side of food supplements? Free Radic Res. 2019. https://doi.org/10.1080/10715762.2019.1636045.

  7. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018. https://doi.org/10.1001/jamanetworkopen2018.3337.

  8. Punzalan C, Budnitz DS, Chirtel SJ, Geller AI, Jones OE, Mozersky RP, et al. Swallowing problems and dietary supplements: data from U.S. Food and Drug Administration Adverse Event Reports, 2006-2015. Ann Intern Med. 2019. https://doi.org/10.7326/M19-0947.

  9. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the physicians’ health study II randomized controlled trial. JAMA. 2012;308:1871–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP diet and health study. J Natl Cancer Inst. 2007;99:754–64.

    CAS  PubMed  Google Scholar 

  11. Crockett SD, Barry EL, Mott LA, Ahnen DJ, Robertson DJ, Anderson JC, et al. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomized clinical trial. Gut. 2018. https://doi.org/10.1136/gutjnl-2017-315242.

  12. Stopsack KH, Greenberg AJ, Mucci LA. Common medications and prostate cancer mortality: a review. World J Urol. 2017;35:875–82.

    CAS  PubMed  Google Scholar 

  13. Bjornsson ES, Hoofnagle JH. Drug-induced liver injury-types and phenotypes. N Engl J Med. 2019;381:264–73.

    PubMed  Google Scholar 

  14. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25:716–29.

    CAS  PubMed  Google Scholar 

  15. Luong JHT, Male KB, Glennon JD. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: an emerging threat. Biotechnol Adv. 2019;37:634–41.

    CAS  PubMed  Google Scholar 

  16. Vroemen WHM, van Doorn WPTM, Kimenai DM, Wodzig WKWH, de Boer D, Bekers O, et al. Biotin interference in high-sensitivity cardiac troponin T testing: a real-world evaluation in acute cardiac care. Cardiovasc Res. 2019. https://doi.org/10.1093/cvr/cvz277.

  17. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomized, double-blind, placebo-controlled study. Mult Scler. 2016;22:1719–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Abdelhak A, Weber MS, Tumani H. Primary progressive multiple sclerosis: putting together the puzzle. Front Neurol. 2017. https://doi.org/10.3389/fneur.2017.00234.

  19. Foley H, Steel A, Cramer H, Wardle J, Adams J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Report. 2019;9:1573. https://doi.org/10.1038/s41598-018-38279-8.

    Article  CAS  Google Scholar 

  20. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Gontero P, Marra G, Soria F, Oderda M, Zitella A, Baratta F, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”? Prostate. 2015;75:1177–86.

    CAS  PubMed  Google Scholar 

  22. Kenfield SA, Van Biarigan EL, DuPre N, Stampfer MJ, Giovannucci LE, Chan JM. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst. 2014. https://doi.org/10.1093/jnci/dju360.

  23. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, et al. Plasma tocopherols and risk of prostate cancer in the selenium and vitamin E Cancer prevention trial (SELECT). Cancer Prev Res (Phila). 2014;7:886–95.

    CAS  Google Scholar 

  24. Vinceti M, Fillippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018;1:CD005195.

    PubMed  Google Scholar 

  25. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014. https://doi.org/10.1093/jnci/djt456.

  26. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010;3:1035–41.

    CAS  Google Scholar 

  27. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Liorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative study. JAMA. 2014;311:33–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s disease cooperative study. N Engl J Med. 1997;336:1216–22.

    CAS  PubMed  Google Scholar 

  29. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin a and selenium trial (PREADVISE). JAMA Neurol. 2017;74:567–73.

    PubMed  PubMed Central  Google Scholar 

  30. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88.

    CAS  PubMed  Google Scholar 

  31. Dysken MW, Kirk LN, Kuskowski M. Changes in vitamin E prescribing for Alzheimer patients. Am J Geriatr Psychiatry. 2009;17:621–4.

    PubMed  Google Scholar 

  32. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (NY). 2019;5:272–93.

    Google Scholar 

  33. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014. https://doi.org/10.1186/alzrt269.

  34. Brunner KT, Hennenberg CJ, Wilechansky RM, Long MT. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep. 2019;8:220–8.

    PubMed  PubMed Central  Google Scholar 

  35. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.

    PubMed  Google Scholar 

  36. Mantovani G, Isidori AM, Moretti C, Di Dato C, Greco E, Ciolli P, et al. Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the “SERENA” study, a randomized, double-blind, placebo-controlled trial. Endocrine. 2019;66:542–50. https://doi.org/10.1007/s12020-019-01958-1.

    Article  CAS  PubMed  Google Scholar 

  37. Pirola I, Rotondi M, Cristiano A, Maffezzoni F, Pasquali D, Marini F, et al. Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: results of the SETI study. Endocrinol Diabetes Nutr. 2019. https://doi.org/10.1016/j.endinu.2019.013.018.

  38. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J. 2018;7:167–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. European group on graves orbitopathy (EUGOGO). The 2016 European thyroid association /European group on graves orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Negro R, Hegedus L, Attanasio R, Papini E, Winther KH. A 2018 European thyroid association survey on the use of selenium supplementation in graves’ hyperthyroidism and graves’ orbitopathy. Eur Thyroid J. 2019;8:7–15.

    PubMed  Google Scholar 

  41. Goossens ME, Zeegers MP, van Poppel H, Joniau S, Ackaert K, Ameye F, et al. Phase III randomized chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer trial. Eur J Cancer. 2016;69:9–18.

    CAS  PubMed  Google Scholar 

  42. Plumelle D, Lombard E, Nicolay A, Portugal H. Influence of diet and sample collection time on 77 laboratory tests on healthy adults. Clin Biochem. 2014;47:31–7.

    CAS  PubMed  Google Scholar 

  43. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1–30.

    Google Scholar 

  44. Caronia LM, Dwyer AA, Hayden D, Amati F, Pitteloud N, Hayes FJ. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf). 2013;78:291–6.

    CAS  Google Scholar 

  45. • Reker D, Blum SM, Steiger C, Anger KE, Sommer JM, Fanikos J, et al. Inactive ingredients in oral medications. Sci Transl Med. 2019. https://doi.org/10.1126/scitransled.aau6753. A comprehensive review of novel prescription drug quality control issues with a focus on the lack of transparency regarding excipient quantity and quality.

  46. FDA.gov https://www.fda.gov. What you need to know about food allergies. Accessed 1 Nov 2019.

  47. Warren CM, Chadha AS, Sicherer SH, Jiang J, Gupta RS. Prevalence and severity of sesame allergy in the United States. JAMA Netw Open. 2019. https://doi.org/10.1001/jamanetworkopen.2019.9144.

  48. • Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labelling accuracy of cannabidiol extracts sold online. JAMA. 2017;318:1708–9. One of the only comprehensive quality control studies, thus far, for internet CBD products, which is symbolic for some of the current OTC issues.

    PubMed  PubMed Central  Google Scholar 

  49. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2:139–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791–804.

    CAS  PubMed  Google Scholar 

  51. Brown HD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019. https://doi.org/10.3390/jcm8070989.

  52. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardo FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17:974–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. www.fda.gov. What you need to know (and what were working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. Accessed 8/21/19.

  54. Benoist GE, van der Doelen MJ, Ter Heine R, van Erp NP, Mehra N. A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. Br J Clin Pharmacol. 2018;84:1064–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55:1369–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. May MB, Glode AE. Apalutamide: a new agent in the management of prostate cancer. J Oncol Pharm Pract. 2019;25:1968–78.

    CAS  PubMed  Google Scholar 

  57. Markham A, Duggan S. Darolutamide: first approval. Drugs. 2019;79:1813–8.

    CAS  PubMed  Google Scholar 

  58. • 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Update AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 67:674–94. An ongoing comprehensive listing of potential medications that should be discouraged in the elderly population or at least approached with caution that has become a gold standard among many diverse health care professionals.

  59. Harnett JE, McIntyre E, Steel A, Foley H, Sibbritt D, Adams J. Use of complementary medicine products: a nationally representative cross-sectional survey of 2019 Australian adults. BMJ Open. 2019. https://doi.org/10.1136/bmjopen-2018-024198.

  60. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368:149–60.

    CAS  PubMed  Google Scholar 

  61. Shipton MJ, Thachil J. Vitamin B12 deficiency-a 21st century perspective. Clin Med (Lond). 2015;15:145–50.

    Google Scholar 

  62. Matrana MR, Gauthier C, Lafaye KM. Paralysis and pernicious anemia in a young woman. J La State Med Soc. 2009;161:228–32.

    PubMed  Google Scholar 

  63. Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96:384–9.

    PubMed  Google Scholar 

  64. DeFilippis EM, Petersen A, Yialamas MA. Progressive weakness and memory impairment in a middle-aged man. JAMA. 2018;320:197–8.

    PubMed  Google Scholar 

  65. Sun Y, Sun M, Liu B, Du Y, Rong S, Xu G, et al. Inverse association between serum vitamin B12 concentration and obesity among adults in the United States. Front Endocrinol. 10:414. https://doi.org/10.3389/fendo.2019.00414.

  66. • Silverstein WK, Lin Y, Dharma C, Croxford R, Earle CC, Cheung MC. Prevalence of inappropriateness of parenteral vitamin B12 administration in Ontario, Canada. JAMA Intern Med. 2019;179:1434–146. An update on how the popular utilization of B12 injections over less costly pills continues to occur, despite the plethora of effectiveness that this practice is antiquated.

    PubMed  PubMed Central  Google Scholar 

  67. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane database Syst rev 2018;3:CD004655. Murali SB. Interpretation of vitamin B12 status after a roux-en-Y gastric bypass. JAMA. 2019;322:887–8.

    Google Scholar 

  68. Chan CQ, Low LL, Lee KH. Oral vitamin B12 replacement for the treatment of pernicious anemia. Front Med (Lausanne). 2016. https://doi.org/10.3389/fmed.2016.00038.

  69. • Meyer HE, Willett WC, Fung TT, Holvik K, Feskanich D. Association of high intakes of vitamins B6 and B12 from food and supplements with risk of hip fracture among postmenopausal women in the Nurses’ Health Study. JAMA Netw Open. 2019. https://doi.org/10.1001/jamanetworkopen.2019.3591. Prospective research suggesting vitamin B12 and B6 supplements in excess of dietary intake could result in adverse effects, but more of this research is needed in men and women.

  70. Price AJ, Travis RC, Appleby PN, Albanes D, Barricarte Gurrea A, Bjorge T, et al. Circulating folate and vitamin B12 and risk of prostate cancer: a collaborative analysis of individual participant data from six cohorts including 6875 cases and 8104 controls. Eur Urol. 2016;70:941–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Tio M, Andricl J, Cox MR, Eslick GD. Folate intake and the risk of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:213–9.

    CAS  PubMed  Google Scholar 

  72. Kim YI. Folate and cancer: a tale of Dr. Jekyl and Mr. Hyde? Am J Clin Nutr. 2018;107:139–42.

    PubMed  Google Scholar 

  73. • Tu H, Dinney CP, Ye Y, Grossman HB, Lerner SP, Wu X. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018;107:208–16. This study raises the issue of folic acid supplementation increasing the risk of bladder cancer recurrence in one of largest prospective series of patients, but also highlights the lack of potential concern from dietary sources of folate.

    PubMed  PubMed Central  Google Scholar 

  74. Pieroth R, Paver S, Day S, Lammersfield C. Folate and its impact on cancer risk. Curr Nutr Rep. 2018;7:70–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies. Int J Food Sci Nutr. 2014;65:286–92.

    CAS  PubMed  Google Scholar 

  76. Bhatt DL. Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al for the REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;389:11–22.

    Google Scholar 

  77. • Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–91. The latest clinical guidelines to suggest some supplements have an effective prescription option and are now endorsed by some of the largest medical/health specialty groups in the U.S., but this manuscript also emphasizes quality control questions with supplement options.

    CAS  PubMed  Google Scholar 

  78. Manson JE, Cook NR, Lee M-I, Christen W, Bassuk SS, Mora S, et al. For the VITAL research group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:33–44.

    CAS  PubMed  Google Scholar 

  79. Castello A, Boldo E, Amiano P, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al. Mediterranean dietary pattern is associated with low risk of aggressive prostate cancer: MCC-Spain study. J Urol. 2018;199:430–7.

    PubMed  Google Scholar 

  80. Aucoin M, Cooley K, Knee C, Fritz H, Balneaves LG, Breau R, et al. Fish-derived omega-3 fatty acids and prostate cancer: a systematic review. Integr Cancer Ther. 2017;16:32–62.

    CAS  PubMed  Google Scholar 

  81. Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, et al. Vitamin D supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. 2019. https://doi.org/10.1001/jamacardio.2019.1870.

  82. Hiemstra T, Lim K, Thadhani R, Manson JE. Vitamin D and atherosclerotic cardiovascular disease. J Clin Endocrinol Metab. 2019;104:4033–50.

    Google Scholar 

  83. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. For the VITAL research group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33–44.

    CAS  PubMed  Google Scholar 

  84. Shea MK, Fielding RA, Dawson-Hughes B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: a randomized trial controlled trial. Am J Clin Nutr. 2019;109:369–79.

    PubMed  Google Scholar 

  85. •• Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA. 2019;322:736–45. A noteworthy and well-done randomized trial demonstrating the opposite impact of the initial intent of the researchers of the trial, and serves as a lesson for why research should guide clinical recommendations, including with supplements.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Letavernier E, Daudon M. Vitamin D, hypercalciuria and kidney stones. Nutrients. 2018. https://doi.org/10.3390/nu10030366.

  87. • Rooney MR, Harnack L, Michos ED, Oglivie RP, Sempos CT, Lutsey PL. Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 International Units daily, 1999–2014. JAMA. 2017;317:2448–50. Documented population evidence of increasing pill utilization, such as vitamin D, being embraced throughout age groups, despite the lack of high-quality direct evidence to support this behavior.

    PubMed  PubMed Central  Google Scholar 

  88. McCrory MA, Harbaugh AG, Appeadu S, Roberts SB. Fast-food offerings in the United States in 1986, 1991, and 2016 show large increases in food variety, portion size, dietary energy, and selected micronutrients. J Acad Nutr Diet. 2019. https://doi.org/10.1016/j.jand.2018.12.004.

  89. Yang C, Shi X, Xia H, Yang X, Liu H, Pan D, et al. The evidence and controversy between dietary calcium intake and calcium supplementation and the risk of cardiovascular disease: a systematic review and meta-analysis of cohort studies and randomized trials. J Am Coll Nutr. 2019. https://doi.org/10.1080/07315724.2019.1649219.

  90. Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381:520–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. De Koning EJ, Lips P, Penninx BWJH, Elders PJM, Heijboer AC, den Heijer M, et al. Vitamin D supplementation for the prevention of depression and poor physical function in older persons: the D-vital study, a randomized clinical trial. Am J Clin Nutr. 2019;110:1119–30.

    PubMed  PubMed Central  Google Scholar 

  92. Scragg R, Khaw KT, Toop L, Sluyter J, Lawes CMM, Waayer D, et al. Monthly high-dose vitamin D supplementation and cancer risk: a post-hoc analysis of the vitamin D assessment randomized clinical trial. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.2178.

  93. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling adults: a systematic review and meta-analysis. JAMA. 2017;318:2466–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M, et al. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319:1600–12.

    PubMed  Google Scholar 

  95. • Kukulijan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, et al. Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. J Clin Endocrinol Metab. 2011;96:955–63. One of the first well-done randomized trials to document the impact of lifestyle changes and diet on bone health in men compared to enhanced supplementation with diet and lifestyle, which begs the question of why more clinical trials are not conducted in this manner.

    Google Scholar 

  96. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the selenium and vitamin E cancer prevention trial (SELECT). Cancer Epidemiol Biomark Prev. 2014;23:1494–504.

    CAS  Google Scholar 

  97. Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013;66:620–2.

    CAS  PubMed  Google Scholar 

  98. McMillan DC, Maguire D, Talwar D. Relationship between nutritional status and the systemic inflammatory response: micronutrients. Proc Nutr Soc. 2019;78:56–67.

    CAS  PubMed  Google Scholar 

  99. • Lyman GH, Greenlee H, Bohike K, Bao T, DeMichele AM, Deng GE, et al. Integrative therapies during and after breast cancer treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol. 2018;36:2647–55. An outstanding comprehensive review of benefits versus harms of integrative therapies in breast cancer, which should serve as a paradigm for other areas of oncology.

    CAS  PubMed  Google Scholar 

  100. Moyad MA. Preventing lethal prostate cancer with diet, supplements, and Rx: heart healthy continues to be prostate health and “first do no harm” part I. Curr Urol Rep. 2018;19:1–9. https://doi.org/10.1007/s11934-018-0846-4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Mark A. Moyad

Authors
  1. Mark A. Moyad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark A. Moyad.

Ethics declarations

Conflict of Interest

Mark Moyad declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Prostate Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moyad, M.A. Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and “First Do No Harm” Part II. Curr Urol Rep 21, 15 (2020). https://doi.org/10.1007/s11934-020-0967-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-020-0967-4

Keywords

Search

Navigation